BETOPTIC PILO Drug Patent Profile

Which patents cover Betoptic Pilo, and when can generic versions of Betoptic Pilo launch?

Betoptic Pilo is a drug marketed by Alcon and is included in one NDA.

The generic ingredient in BETOPTIC PILO is betaxolol hydrochloride; pilocarpine hydrochloride. There are eleven drug master file entries for this compound. Additional details are available on the betaxolol hydrochloride; pilocarpine hydrochloride profile page.

Summary for BETOPTIC PILO

US Patents:	0
Applicants:	1
NDAs:	1
Clinical Trials:	1
DailyMed Link:	BETOPTIC PILO at DailyMed

Recent Clinical Trials for BETOPTIC PILO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Alcon Research	Phase 3

See all BETOPTIC PILO clinical trials

US Patents and Regulatory Information for BETOPTIC PILO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alcon	BETOPTIC PILO	betaxolol hydrochloride; pilocarpine hydrochloride	SUSPENSION/DROPS;OPHTHALMIC	020619-001	Apr 17, 1997		DISCN	No	No

Expired US Patents for BETOPTIC PILO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Alcon	BETOPTIC PILO	betaxolol hydrochloride; pilocarpine hydrochloride	SUSPENSION/DROPS;OPHTHALMIC	020619-001	Apr 17, 1997	5,635,172

International Patents for BETOPTIC PILO

See the table below for patents covering BETOPTIC PILO around the world.

Country	Patent Number	Title	Estimated Expiration
Mexico	9203521	FORMULACION DE ALIVIO, DE LIBERACION SUSTENTADA PARA TERAPIA DE GLAUCOMA.
Japan	2854418
Australia	1607495
European Patent Office	0741563

Market Dynamics and Financial Trajectory for Betoptic Pilo

Last updated: February 4, 2026

Betoptic Pilo (betaxolol hydrochloride ophthalmic solution) is primarily used for glaucoma and ocular hypertension management. The drug's market performance depends on regulatory, patent, production, and competitive factors. Financial projections hinge on sales volume, pricing strategies, market penetration, and competition.

Market Dynamics

Regulatory and Patent Status

Betoptic Pilo was approved by the FDA in the 1980s. Its patent expiration occurred around 2011, allowing generic versions to enter the market. The loss of patent exclusivity significantly affected pricing power, leading to increased generic competition.

Competitive Landscape

Several generics are available globally, including betaxolol-based formulations from Teva, Sandoz, and others. Newer glaucoma drugs, such as prostaglandin analogs (latanoprost, bimatoprost) and combination therapies (Dorzolamide-Timolol), have shifted prescriber preferences toward products with fewer dosing requirements or better efficacy profiles.

Market Penetration

Betoptic Pilo's market share declined considerably post-patent expiry, with broader adoption of generics and alternative treatments. However, it remains used in specific regions due to formulary familiarity and clinical familiarity with beta-blocker therapy, particularly in patients intolerant to prostaglandins.

Pricing and Reimbursement

Prices vary globally. In the US, branded Betoptic Pilo was historically priced higher than generics; now, prices for generics are substantially lower, influencing revenue. Reimbursement policies favor generics, further pressuring traditional branded formulations.

Financial Trajectory

Factor	Impact on Revenue	Details
Patent expiry	Decline	Loss of exclusivity has led to generic price erosion.
Market share	Declining	Shift toward newer agents and generics.
Pricing	Decreased	Price competition from generics reduces revenue per unit.
Volume	Stable or slightly declining	Long-term use in glaucoma remains common, but market share diminishes.
Competition	Increasing	New drugs and combination therapies limit Betoptic Pilo's growth potential.

Forecast Estimates (Next 5 Years)

• Worldwide sales are expected to decline at a compound annual growth rate (CAGR) of -4% to -6%, primarily due to market saturation and competition.
• Regional Variance: The US market will contract faster than emerging markets where access to affordable generics remains limited.
• Potential Niche Markets: Use in specific patient groups or regions with limited access to newer drugs could sustain minor revenues.

Key Market Trends

• Growth in combination therapies reduces monotherapy sales.
• Increasing adoption of minimally invasive glaucoma surgeries (MIGS) alters long-term treatment patterns.
• Patent and exclusivity extensions are less common for older molecules like Betoptic Pilo.

Conclusion

Betoptic Pilo’s financial outlook is characterized by a declining trajectory driven by generic competition, evolving treatment protocols, and competitive alternatives. Its market relevance sustains in specific niches; however, its overall revenue diminishes amid broader shifts in glaucoma management.

---

Key Takeaways

• Patent expiry in 2011 reduced Betoptic Pilo's pricing power.
• Market share declines amid the rise of generic formulations and alternative therapy options.
• Globally, sales are projected to decline at a rate of roughly 4-6% annually over the next five years.
• Regional variations create pockets of sustained demand, chiefly in developing markets.
• Newer drug classes and surgical options influence long-term treatment patterns, impacting future revenue.

---

FAQs

1. What factors influence Betoptic Pilo’s declining sales?
Patent expiration, generic competition, and the introduction of newer glaucoma treatments primarily drive the decline in sales.

2. Are there any regulatory plans to extend Betoptic Pilo’s market life?
No recent plans for patent extensions or new formulations exist; focus shifts toward new therapeutic classes and devices.

3. How does pricing affect Betoptic Pilo’s market share?
Lower prices of generics constrain revenue for branded formulations; price sensitivity varies by region.

4. What are the main competitors for Betoptic Pilo?
Prostaglandin analogs, combination therapies like Dorzolamide-Timolol, and surgical interventions.

5. Can Betoptic Pilo find niche applications in future glaucoma management?
Potentially in regions with limited access to newer drugs or in specific patient populations intolerant to alternative therapies.

---

Citations

1. U.S. Food and Drug Administration (FDA). Drug approval records.
2. Market Research Future. "Global Glaucoma Drugs Market," 2022.
3. IMS Health (IQVIA). "Pharmaceutical Market Trends," 2022.
4. EvaluatePharma. "Top-selling Ophthalmic Drugs," 2022.
5. Global Data. "Glaucoma Market Analysis," 2022.